Citigroup
TRIV

Citigroup’s TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK TRIV Stock Holding History

Citigroup’s Portfolio TRIV Stock Details TRIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-500
Closed -$3K – 8142
2015
Q4 		$3K Hold
500
– – ﹤0.01% 7231
2015
Q3 		$3K Hold
500
– – ﹤0.01% 6973
2015
Q2 		$3K Buy
500
+92
+23% +$653 ﹤0.01% 7079
2015
Q1 		$4K Sell
408
-868
-68% -$8.94K ﹤0.01% 6835
2014
Q4 		$16K Buy
1,276
+967
+313% +$13.2K ﹤0.01% 6317
2014
Q3 		$5K Buy
309
+246
+390% +$3.57K ﹤0.01% 6606
2014
Q2 		$1K Buy
+63
New +$956 ﹤0.01% 7047

Citigroup's TRIV Position: Q1 2016 in Review

Citigroup sold out of TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK (TRIV) in Q1 2016, closing a stake of 500 shares — an estimated $3K sold.

Citigroup first reported a position in TRIV in Q2 2014 and held it in 7 quarters. The position peaked at $16K in Q4 2014. 0 funds tracked by Wall St. Rank hold TRIV as of Q1 2016.

  • Citigroup reported no remaining TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK position as of Q1 2016 after selling out during the quarter.
  • Citigroup sold 500 TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK shares in Q1 2016, an estimated $3K.
  • Citigroup first reported a position in TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK in Q2 2014 and held it in 7 quarters.
  • Citigroup's TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK position peaked at $16K in Q4 2014.
  • 0 funds tracked by Wall St. Rank held TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK as of Q1 2016.

Based on Citigroup's 13F filing for Q1 2016, filed 13 May 2016.